FDA 483 - CSL Plasma Inc. - May 02, 2019

CSL PLASMA in Philadelphia, PA, was inspected from April 16 to May 2, 2019, revealing a significant issue regarding the presence of medical staff. The firm failed to ensure a responsible physician or physician substitute was on the premises during critical donor eligibility determinations and blood collection activities. This indicates a lapse in direct medical oversight for source plasma operations.